Breast cancer trial lets early response guide treatment switch
NCT ID NCT07616453
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study tests a personalized approach for women with a common type of early breast cancer (HR+/HER2-). All 45 participants start with a combination of culmerciclib and hormone therapy. If the tumor responds well, they continue; if not, they switch to a different treatment before surgery. The goal is to improve outcomes and avoid ineffective therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Culmerciclib (a CDK2/4/6 inhibitor) plus aromatase inhibitors (letrozole or anastrozole)
What this could lead to
If successful, this could show that adapting treatment based on early response improves outcomes and avoids ineffective therapy for people with a common type of breast cancer.
What could go wrong
This is a small, early-phase study (45 people) without a control group, so results may not be definitive. The drug combination may cause side effects or fail to improve response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact